Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGO trial of colchicine versus placebo in acute myocarditis
2022-002563-29Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myocarditis comparing Colchicine with Placebo (2 arms). Primary endpoint: Inflammatory myocardial damage or clinical outcome at 6 months. Started Jan 2023; status: active.
02
Drugs
colchicine
03
Conditions
acute myocarditis
Beyond the preview
Go deeper on 2022-002563-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002563-29.